Why the study?
Elevated LDL-C is causal to atherosclerosis and reducing LDL-C is a major objective for cardiovascular disease prevention, with novel lipid-lowering therapies emerging beyond statins.
This review highlights the development and clinical availability of novel lipid-lowering therapies beyond statins, such as bempedoic acid, PCSK9 inhibitors, and ANGPTL3 inhibitors, for cardiovascular disease prevention.
PURPOSE OF REVIEW: Elevated levels of low-density lipoprotein cholesterol (LDL-C) are causal to atherosclerosis and, thus, the reduction of LDL-C represents a major objective for the prevention of cardiovascular disease. Aim of this review is to provide an overview on novel strategies to lower LDL-C. RECENT FINDINGS: Although inhibiting liver cholesterol biosynthesis by statins is used as the main therapeutic approach to increase hepatic LDL-receptor expression and lower plasma cholesterol levels, novel insights into lipid and lipoprotein biology have led to the development of additional lipid-lowering therapies that can be used in combination with or as an alternative to statins in patients with statin-intolerance. New approaches include bempedoic acid, proprotein convertase subtilisin/kexin type 9 inhibitors, and angiopoietin-like protein 3 inhibitors. SUMMARY: In the last decade, several novel therapeutic approaches have been tested and some of them have been approved as lipid-lowering agents. Some drugs are already available in clinical practice, whereas others are at late stages of development.
No takes yet. Share an insight, caveat, or question.
Pirillo et al. (2020) conducted a review in Elevated low-density lipoprotein cholesterol (LDL-C). Novel lipid-lowering therapies (bempedoic acid, PCSK9 inhibitors, ANGPTL3 inhibitors) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: